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ABSTRACT 
Heart failure (HF) and atrial fibrillation (AF) are amongst the commonest 
cardiovascular conditions encountered in clinical practice and frequently 
coexist. Over the last decade, they have evolved into global cardiovascular 
epidemics. This, in turn, has huge clinical and economic implications. 
There is ample evidence that AF and HF have a mutually deleterious effect on 
each other. AF is not only a marker of HF severity but also affects HF 
prognosis independently.  
This article presents the close pathophysiological relationship between AF 
and HF and the adverse prognostic consequences of this bi-directional 
interaction. The scope of various therapeutic modalities and their potential 
impacts are discussed briefly. 
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KEY POINTS 
1. HF and AF have been recognised as global cardiovascular epidemics. 
2. They frequently co-exist, are inter-dependent and have a mutually 
adverse prognostic impact. 
3. Rate control remains the mainstay of therapy with rhythm control 
reserved for a specific group of patients. 
4. Stroke prevention is one of the most important aspects of AF care in 
the HF population. 
KEY WORDS  
Atrial fibrillation, Heart failure, Pathophysiology, Prognosis, 
Thromboprophylaxis.
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INTRODUCTION 
 Heart failure (HF) and atrial fibrillation (AF) are amongst the 
commonest cardiovascular conditions encountered in clinical practice and 
frequently coexist. Up to 40% of patients with HF either have or go on to 
develop AF and approximately 40% of patients with AF present with (or 
develop) HF.1 Heart failure predicts the development of AF and conversely the 
presence of AF predicts the development of HF. Both are increasingly 
prevalent phenotypic manifestations of a multitude of different primary or 
secondary cardiac pathologies (see figure 1).  
 The prevalence of HF and AF has steadily increased over the years. 
This is in part through an ageing population and as development of more 
effective therapy improves outcomes associated with other cardiovascular 
conditions (such as myocardial infarction). In Europe, HF has an estimated 
prevalence of 30 million with 1 in 5 lifetime-odds of developing HF.2  Similarly 
2% of Europeans have AF with a projected prevalence of 14 -17 million by the 
year 2030.3 The lifetime risk of AF is 1 in 4 (as derived from community-based 
cohorts in Framingham and Rotterdam studies).  
 
INTERACTIONS BETWEEN HF AND AF 
a) Prognosis 
 The presence of AF is associated with an increased risk of mortality in 
patients with HF.4 This adverse prognosis is observed in patients with left 
ventricular (LV) systolic dysfunction (HF with reduced ejection fraction – 
HFREF) as well as those with preserved left ventricular function (i.e. HF with 
preserved LV systolic function – HFPEF). For instance, the SOLVD (Studies 
Of Left Ventricular Dysfunction) trial demonstrated that even in asymptomatic 
patients with an LV ejection fraction of <35%, mortality was 34% when AF 
was present and 24% when it was not. The mortality in new onset AF (12%) 
was also greater than for persistent AF (7%).5 Sub-group analysis of the 
CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality 
and morbidity) study revealed that AF has an independent and deleterious 
effect on long-term all-cause cardiovascular mortality in HF patients. The 
absolute mortality risk was highest in patients with LVEF <35%, however, 
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those with HFPEF had the highest relative risk of death (HR 1.37, 95% CI 
1.06 to 1.79) in contrast to HFREF (HR 1.22, 95% CI 1.04 to 1.43).6  Similarly, 
meta-analysis by Mamas et al. (using data derived from 16 studies and 
incorporating over 50,000 patients) showed that AF has a negative impact on 
total HF mortality with an odds ratio of 1.40 (95% CI 1.32-1.48, P<0.0001) in 
randomised trials and 1.14 (95% CI 1.03-1.26, P<0.05) in observational 
studies. Again, this was applicable to HFREF as well as HFPEF patients.4  
 We have previously summarised scientific evidence showing the 
negative prognostic effect of AF in HF patients (See Tables 1 and 2).7 
However, it is not entirely clear whether AF per se is the cause of increased 
mortality or merely a marker of more advanced HF. 
b) Symptoms of HF 
 AF is more likely to occur in patients with more severe HF symptoms 
(e.g., NYHA I - 10%, NYHA 4 – 50%). Prolonged exposure to AF with a fast 
ventricular response also contributes to LV systolic dysfunction – a 
tachycardiomyopathy. 
c) Stroke risk 
 AF confers a greater degree of stroke risk in HF patients as the 
presence of HF carries a weighting of 1 point in the CHADSVASC risk 
stratification tool for AF and stroke. The risk of stroke is equivalent both in 
HFREF and HFPEF alike at a rate of up to 4.4% per 100 patient years.8  
 
TREATMENT OF AF IN PATIENTS WITH HF 
Treatment algorithms for both are extensively discussed in guidelines 
elsewhere 9 and are beyond the scope of this article. However, the main 
principles of the treatment of AF in patients with HF can be summarised as 
follows: 
a) Rate or rhythm control 
The commonest form of rate control is with AV nodal blocking agents 
such as beta blockers, rate controlling calcium channel antagonists (provided 
LV systolic function is preserved) and digoxin. 9 Management of both 
occurring together is extrapolated from trials in AF that contain between 20 – 
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30% of patients with HF and HF trials that contain between 10-30% of 
patients with AF.  
The optimum target rate to achieve in AF is, however, difficult to determine 
with any degree of precision. Current guidelines define adequate rate control 
in atrial fibrillation as maintenance of the ventricular rate response between 60 
and 80 beats/min at rest and between 90 and 115 beats/min during moderate 
exercise. 
Special considerations for AF ventricular rate control in HF include: 
• The optimum heart rate suggested in the AF-CHF trial (in which rate 
versus rhythm strategies were compared in HFREF patients) was 80 
bpm at rest and <110 bpm with exertion. This trial also demonstrated 
no significant benefit in rhythm compared to rate control.11 
• Beta blockers are the most commonly indicated. 9 It is unclear whether 
the beneficial prognostic effects of beta blockers in sinus rhythm in 
patients with HFREF are generalizable to similar patients with AF10, but 
currently beta blockers remain the preferred rate control agent in 
HFREF. 
• Digoxin is suggested in patients unable to tolerate beta blockers – this 
may include patients with acute decompensated HF in whom the 
negative inotropic effect of beta blockers may exacerbate congestion.  
• The role of cardiac glycosides in HF and AF has lately become 
controversial due to reports suggesting increased mortality in HF and 
AF patients on digoxin therapy.11 This evidence is based on 
observational studies and post hoc analysis and should therefore be 
viewed with these limitations in mind. So far, DIG trial is the only 
randomised controlled trial (RCT) in patients with HF and sinus rhythm 
but it did not present a direct comparison between digoxin and other 
rate control agents. On the other hand, there is no RCT studying 
patients in AF with digoxin. Moreover, there is the confounding bias 
that physicians are likely to prescribe digoxin in patients who are more 
unwell and may have a higher overall mortality anyway. Nevertheless, 
it would be prudent to say that till we have more robust data available, 
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digoxin should be used with caution in HF patients keeping serum 
levels less than 1.2 ng/mL.12  
 
On the other hand, rhythm control strategies (using anti-arrhythmic 
medications) have shown no benefit over rate control in terms of mortality, 
stroke prevention or hospitalisation. However, they can be reserved for 
patients who are intolerant to rate control medications or remain symptomatic 
despite adequate rate control. A number of trials have looked at rate versus 
rhythm control. AF-CHF (Atrial Fibrillation in Congestive Heart Failure) trial 
prospectively randomized 1376 HFREF patients to amiodarone or rate control 
medication. The cohort was followed up for 3 years looking at all-cause 
mortality, stroke and HF admission. The difference in mortality in the two arms 
was not significant (27% and 25% respectively). In addition, there was 
increased morbidity from torsades and bradycardia in the rhythm control 
arm.13 Similarly, Atrial Fibrillation Follow-up Investigation of Rhythm 
Management (AFFIRM)14 and Rate Control versus Electrical Cardioversion for 
Persistent Atrial Fibrillation (RACE)15 trials have demonstrated similar 
findings. The latter, however, were not exclusive to HF patients and arguably, 
were under-represented by a younger patient cohort who may be more 
symptomatic as well as in an earlier phase of the disease and thus, are likely 
to gain more from rhythm control as compared to a rate control strategy. It 
follows, therefore, that rhythm control should be reserved for patients who are 
particularly symptomatic with AF despite adequate rate control. 
Since medications used for rhythm control (e.g. class 1a, class 1c agents, 
dronedarone) all have an increased mortality in HFREF, any rhythm-control 
technique that obviates the need for antiarrhythmic agents offers a clear 
advantage. Pulmonary vein isolation by using various catheter ablation 
techniques has emerged as an encouraging option in this regard. Its role in 
HF has shown early promise, but remains to be defined 16 particularly in terms 
of long-term prognosis. To date, a number of small trials have shown very 
promising results17, 18 (as risks of the procedure are not increased and 
mortality appears to be improved) while larger randomised trials are 
underway19, 20. Depending upon the results, AF ablation may potentially 
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become an important first-line option in patients with HF.  Finally, surgical 
ablation techniques (such as Cox Maze procedure) are available to patients 
undergoing cardiac surgery. They have been shown to be safe and effective 
including in patients with HF.  
Pacing strategies can also be employed in patients with both AF with a fast 
and slow ventricular response (bradycardia pacing with subsequent rate 
control medications) and in patients with refractory AF with fast ventricular 
response (pacemaker implantation with subsequent AV node ablation). This 
"pace-and-ablate" strategy, however, does not eliminate AF per se. Studies 
conducted so far are small, non-randomised and mostly from single centres. 
Results are promising but further larger trials are warranted. 
 Lastly, development of newer anti-arrhythmic drugs such as selective 
atrial-specific ion-channel blockers (e.g., Vernakalant) may offer an advantage 
over previously available ones but their role in HF population needs further 
studies.  
b) Thromboprophylaxis 
Patients with AF and HF have their risk of stroke and systemic 
embolism doubled as compared to either condition alone.21 Hence, 
thromboprophylaxis with oral anticoagulants is of paramount importance and 
has been shown to be safe and effective.22 Warfarin is thrice as effective as 
aspirin and novel oral anticoagulants (NOACs) are at least as good as 
warfarin. NOACs include inhibitors of either thrombin (Dabigatran) or activated 
factor X (Apixaban, Edoxaban and Rivaroxaban).  Results from major trials 
(RELY, ARISTOTLE, ENGAGE AF-TIMI48, ROCKET respectively) have been 
encouraging.23 Dabigatran was the first NOAC introduced into clinical 
practice. Comparison with warfarin in the RELY trial shows that its dose of 
110mg twice daily  is superior for bleeding but non-inferior for thromboembolic 
protection while 150mg twice daily  is non-inferior for bleeding but superior for 
thromboembolic protection. Apixaban, on the other hand, has been shown to 
be superior to warfarin in efficacy and associated with less gastrointestinal, 
intracranial and other major bleeding. Other factor X inhibitors are non-inferior 
to warfarin and associated with less intracranial and other major bleeding but 
higher gastrointestinal haemorrhage. Rivaroxaban and Edoxaban have the 
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added advantage of being once daily as well. Importantly, several NOAC 
reversal agents are currently in development and Idarucizumab (which is a 
fully humanized monoclonal antibody fragment) has recently received global 
approval as a specific reversal agent for Dabigatran.24  
Finally, a small number of patients are unable to receive oral 
anticoagulation due to drug intolerance or bleeding contra-indications. Left 
atrial appendage occlusion devices (such as Watchman device) hold promise 
in such cases but need further experience and long-term data.25  
 
CONCLUSIONS 
 The prevalence of both AF and HF are increasing and they frequently 
co-exist. Concurrence of AF and HF is associated with a higher risk of 
morbidity and mortality than either condition alone. There is no clear-cut 
evidence so far that rhythm control is superior (in terms of long-term mortality) 
to rate control. Radiofrequency catheter intervention techniques are promising 
and it is hoped that larger trials (looking at outcome data) would help 
incorporate these into the standard management algorithm. Finally, novel oral 
anticoagulants are a welcome addition to the therapeutic armamentarium 
available to the clinician. Future insights into mechanisms of disease and 
development of new therapeutic modalities continues to hold promise in this 
challenging field. 
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TABLES 
 
Table 1. Prognostic impact of AF in HF: Summary of randomised trials  
 
Author Setting Number LVEF 
Mean 
follow 
up 
(years) 
%AF 
Number (%) deaths 
P-VALUE 
SR AF 
Carson et al.  V-HEFT I&II 1427 LVEF <45% 2.5  19 480/1221 (39) 
75/206 
(36) NS 
Dries et al. SOLVD 6517 LVEF< 35% 2.8  6 1395/8098 (23) 
149/419 
(34) <0.0001 
Mathew et al.  DIG 7788 All LVEF included 3.1  11 
2231/6922 
(32) 
375/866 
(43) <0.0001 
Crijns et al.  PRIME II 409 LVEF<35% 3.4  21 153/325 (47) 50/84 (60) <0.05 
Swedberg et al.  COMET 3029 LVEF<35% 4.8  20 874/2429 (36) 
258/600 
(43) <0.0005 
Olsson et al.  CHARM 7601 All LVEF included 3.1  15 
1466/6451 
(23) 
365/1148 
(32) <0.001 
Pederson et al.  DIAMOND 3587 LVEF< 35% N/A 24 1951/2661 (73) 
634/818 
(77) <0.001 
 SR: sinus rhythm; AF: atrial fibrillation; LVEF: left ventricular ejection fraction. 
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Table 2. Prognostic impact of AF in HF: Summary of observational studies  
 
Author Setting Number LVEF Mean follow up %AF 
Number (%) deaths 
P-VALUE SR AF 
Middlekauff et 
al.  
Heart 
Transplantation 390 
LVEF < 
35% 265 days 19 
123/315 
(29) 36/75 (48) <0.005 
Stevenson et al.  Heart Transplantation 750 
LVEF < 
40% 2.0 years 22 
336/584 
(45) 
104/160 
(61) <0.01 
Mahoney et al.  Heart Transplantation 234 
LVEF < 
45% 1.1 years 27 26/171 (15) 14/63 (22) NS 
Ahmed et al.  Medicare Alabama 944 All LVEF included 4.0 years 27 
439/711 
(62) 
166/233 
(71) <0.01 
Wojtkowska et 
al.  Bilaystok, Poland 120 
LVEF < 
30% 3.0 years 50 26/60 (43) 33/60 (55) NS 
Corell et al.  Danish HF clinic Network 1019 
LVEF < 
45% 1.9 years 26 
180/750 
(24) 
89/269 
(33) <0.05 
Pai and 
Varadarajan Loma Linda VA 8931 
All LVEF 
included 2.5 years 18 
2164/7728 
(28) 
529/1203 
(44) <0.0001 
Rivero-Ayerza 
et al.  
EuroHeart Failure 
Survey 10701 
All LVEF 
included N/A 43 
419/6027 
(7) 
372/4674 
(8) <0.05 
Rusinaru et al.  Somme< France 368 LVEF> 50% N/A 36 
125/236 
(53) 
84/132 
(64) <0.05 
Hamaguchi et 
al.  
Japanese Registry 
data 2659 
All LVEF 
included 2.4 years 35 N/A N/A NS 
Shotan et al.  National HF Survey, Israel 4102 
All LVEF 
included 4 years 33 
1480/2734 
(54.3) 
882/1359 
(64.9) 0.0001 
SR: sinus rhythm; AF: atrial fibrillation; LVEF: left ventricular ejection fraction. 
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HEART FAILURE SYNDROME 
Figure 1 : Interrelation between HF and AF demonstrating the 
causality of each and the mechanisms for one worsening the 
other. (Modified from Anter et al. Circulation 2009 May 12; 
119(18):2516-25) 
 
